Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis

Table 1

The pooled incidence rate of AST and ALT abnormalities.

Characteristics		Incidence (%)	95% CI		I^2 (%)
AST increase
All grades	Uninfected	14.17	5.18%–25.86%	0.086	51.01
	HCV	24.20	4.79%–50.46%	<0.001	83.11
	HBV	12.26	5.61%–20.71%	0.026	60.63
	Hepatitis	16.93	8.32%–27.45%	<0.001	76.97
Grades 3-4	Uninfected	3.16	0.01%–9.43%	0.211	31.57
	HCV	17.37	5.51%–32.96%	0.043	59.43
	HBV	3.09	0.34%–7.56%	0.121	42.57
	Hepatitis	7.69	2.30%–15.13%	<0.001	71.08
ALT increase
All grades	Uninfected	8.56	1.49%–19.19%	0.096	52.79
	HCV	36.07	11.45%–64.51%	<0.001	79.99
	HBV	13.07	5.62%–22.48%	0.041	56.84
	Hepatitis	21.27	10.91%–33.49%	0.210	33.65
Grades 3-4	Uninfected	2.25	0.00%–8.19%	0.293	19.17
	HCV	9.39	2.19%–19.43%	0.409	1.10
	HBV	0.95	0.00%–3.66%	0.044	46.65
	Hepatitis	3.48	0.37%–8.46%	0.210	33.65